Researchers have found that both CBD and THC show noteworthy anti-cancer activity against ovarian cancer cells in laboratory experiments, suggesting potential usefulness for future therapies, according to a recent ScienceDaily report. The study, published in Frontiers in Pharmacology, highlights how these naturally occurring cannabinoids may slow tumor growth and contribute to cancer cell death.
In tests using two ovarian cancer cell lines, one sensitive to standard platinum-based chemotherapy and one resistant, both CBD and THC reduced cell growth and colony formation when applied individually. However, the most pronounced effects were observed when the compounds were combined in a roughly 1:1 ratio, slowing cancer cell reproduction and substantially reducing cellular migration, a key factor in metastasis.
The researchers found that CBD and THC together may help modulate a key internal system that cancer cells use to grow and survive: the PI3K/AKT/mTOR pathway. This system is often stuck in overdrive in ovarian cancer, allowing tumors to spread and resist treatment. By restoring that system to normal activity, the cannabinoids appeared to slow cancer cell growth and increase cancer cell death, according to the report.
Despite the promising lab results, the researchers note that these findings are preliminary and derived from in vitro work. Before this research can lead to any real-world treatments, further testing is needed with human subjects. Regulatory and legal barriers surrounding cannabis research make it difficult to establish official therapeutic options for doctors to recommend, though non-pharmaceutical medical cannabis is widely available in numerous U.S. states.
